The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S ...

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...

Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...

BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase 3 trial showed a sustained clinical benefit from long-term ...

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: ...

This activity has been designed to address the educational needs of sports medicine clinicians (physicians and advanced practice providers), orthopedic surgeons, and medical and surgical oncology ...